Cardoneb 5 mg (Tablet)
Unit Price: ৳ 10.00 (3 x 10: ৳ 300.00)
Strip Price: ৳ 100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Nebivolol hydrochloride |
| Company | Eskayef pharmaceuticals ltd |
| Also available as |
Indications
- Hypertension
- Treatment of essential hypertension
- Chronic heart failure (CHF)
- Treatment of stable mild and moderate chronic heart failure in elderly patients
Pharmacology
- Beta adrenergic receptor blocking agent
- Inhibits beta1 and beta2 adrenergic receptors
- Lacks intrinsic sympathomimetic and membrane stabilizing activity
- Decreased heart rate
- Decreased myocardia contractility
- Diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers
- Suppression of renin activity
- Vasodilation and decreased peripheral vascular resistance
- Metabolized by routes including glucuronidation and hydroxylation by CYP2D6
- Mean peak plasma nebivolol concentrations occur approximately 1.5 to 4 hours post-dosing
- Plasma protein binding of nebivolol is approximately 98%
- Primarily metabolized via direct glucuronidation of parent
Dosage & Administration
- Recommended starting dose is 5 mg once daily
- Dose can be increased at 2-week intervals up to 40 mg
- More frequent dosing regimen is unlikely to be beneficial
Interactions
- Concurrent use with myocardial depressants or inhibitors of AV conduction
- Contraindicated with other beta-blockers
- Use caution when co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.)
Contraindications
- Severe bradycardia
- Heart block greater than first degree
- Cardiogenic shock
- Decompensated cardiac failure
- Sick sinus syndrome (unless a permanent pacemaker is in place)
- Severe hepatic impairment (Child-Pugh >B)
- Hypersensitivity to any component of this product
Side Effects
- Headache
- Nausea
- Bradycardia
Precautions & Warnings
- Abrupt cessation advisement for patients with coronary artery disease
- Caution in patients with compensated congestive heart failure
- Not studied in patients with angina pectoris or recent MI
- Patients with bronchospastic diseases should not receive beta-blockers
- Close monitoring during anesthesia and major surgery
- Caution in patients with diabetes and hypoglycemia
- Caution in patients with thyrotoxicosis
- Exercise caution in patients with peripheral vascular disease
- Caution with concomitant use of non-dihydropyridine calcium channel blockers
Use in Special Populations
- Use with caution in patients with severe renal impairment
- Use with caution in patients with moderate hepatic impairment
- Risk of anaphylactic reactions
Therapeutic Class
- Beta-adrenoceptor blocking drugs
- Beta-blockers
Storage Conditions
- Keep below 30°C temperature
- Keep away from light & moisture
- Keep out of the reach of children